Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for ... Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies and CAR T therapies for solid tumors. 더 보기
WORCESTER, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.27 | 6.32318501171 | 4.27 | 6.7 | 3.72 | 1141503 | 4.40960872 | CS |
4 | 4.36 | 2422.22222222 | 0.18 | 6.7 | 0.1066 | 27707441 | 0.25826672 | CS |
12 | 4.2948 | 1751.5497553 | 0.2452 | 6.7 | 0.1066 | 8817337 | 0.25476988 | CS |
26 | 4.1794 | 1159.01275652 | 0.3606 | 6.7 | 0.1066 | 4770726 | 0.2632548 | CS |
52 | 3.06 | 206.756756757 | 1.48 | 6.7 | 0.1066 | 9879362 | 0.57834994 | CS |
156 | -11.51 | -71.7133956386 | 16.05 | 18.45 | 0.1066 | 3575084 | 1.32687808 | CS |
260 | -55.16 | -92.3953098827 | 59.7 | 78.3 | 0.1066 | 2738904 | 12.18937272 | CS |
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관